Choosing Appropriate Estimands in Clinical Trials

被引:0
|
作者
Ann-Kristin Leuchs
Jörg Zinserling
Andreas Brandt
Dorothee Wirtz
Norbert Benda
机构
[1] Federal Institute for Drugs and Medical Devices (BfArM),
关键词
clinical trials; estimands; efficacy; effectiveness; nonadherence; missing data;
D O I
暂无
中图分类号
学科分类号
摘要
Lack of adherence to study protocol and missing data are often unavoidable in clinical trials, and both increase the need to differentiate between the ideal treatment effect if the medication is taken as directed and the treatment effect in presence of the actual adherence pattern. In this regard, estimands have become the focus of attention. An estimand is simply that which is being estimated. In the context of treatment benefit, an estimand may address either efficacy or effectiveness aspects. Defining the estimand of interest is an essential step to take before deciding on trial design and primary analysis. The choice of estimand has consequences for various other factors to be considered during any clinical trial’s planning phase. This study presents a process chart including all aspects to consider during planning. After deciding on the primary estimand, the trial design should be specified, followed by the primary analysis. Both should appropriately address the chosen estimand. Finally, sensitivity analyses should be taken into account. Provided are suggestions for all the planning steps involved, especially on choosing between efficacy and effectiveness, and relevant examples from clinical practice to illustrate them. It is recommended that one bear in mind the process chart during planning of any clinical trial and give reasonable justification for each decision in the study protocol.
引用
收藏
页码:584 / 592
页数:8
相关论文
共 50 条
  • [1] Choosing Appropriate Estimands in Clinical Trials
    Leuchs, Ann-Kristin
    Zinserling, Joerg
    Brandt, Andreas
    Wirtz, Dorothee
    Benda, Norbert
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 584 - 592
  • [2] Choosing Appropriate Estimands in Clinical Trials (Leuchs et al): Letter to the Editor
    Garrett, Andrew
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 601 - 601
  • [3] Choosing Appropriate Estimands in Clinical Trials (Leuchs et al): Letter to the Editor
    Andrew Garrett
    [J]. Therapeutic Innovation & Regulatory Science, 2015, 49 : 601 - 601
  • [4] Choosing estimands in clinical trials with missing data
    Mallinckrodt, Craig
    Molenberghs, Geert
    Rathmann, Suchitrita
    [J]. PHARMACEUTICAL STATISTICS, 2017, 16 (01) : 29 - 36
  • [5] The detailed clinical objectives approach to designing clinical trials and choosing estimands
    Bell, James
    Hamilton, Alan
    Sailer, Oliver
    Voss, Florian
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (06) : 1112 - 1124
  • [6] A structured approach to choosing estimands and estimators in longitudinal clinical trials
    Mallinckrodt, C. H.
    Lin, Q.
    Lipkovich, I.
    Molenberghs, G.
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (06) : 456 - 461
  • [7] Choosing appropriate estimators for estimands in PRO endpoints
    Skaltsa, Konstantina
    Iva-Nescu, Cristina
    [J]. QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S26 - S26
  • [8] Estimands and Their Role in Clinical Trials
    Akacha, Mouna
    Bretz, Frank
    Ohlssen, David
    Rosenkranz, Gerd
    Schmidli, Heinz
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (03): : 268 - 271
  • [9] Estimands in diabetes clinical trials
    Min, Thinzar
    Bain, Stephen C.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (03): : 181 - 183
  • [10] Causal Inference and Estimands in Clinical Trials
    Lipkovich, Ilya
    Ratitch, Bohdana
    Mallinckrodt, Craig H.
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 54 - 67